Area: Oncology , Respiratory
Location: Geneva, Switzerland
Date: April 15 to April 18
Description:
European Lung Cancer Conference
Role of immunoncology in lung cancer treatment
Immunotherapy in lung cancer
Important recent developments in oncology
EGFR and ALK mutations in NSCLC
Sequencing the mesothelioma genom
The proper treatment algorithm for non-oncogene driven NSCLC
Phase 2 trial of nivolumab in NSCLC
Multidisciplinary approach in lung cancer treatment
Immunotherapy as first-line treatment for NSCLC
LBA2_PR - EGFR mutation testing and oncologist treatment choice in advanced NSCLC
Role of checkpoint inhibitors in lung cancer treatment
Targeted therapy in lung cancer
The Lung Cancer Master Protocol
Surgical perspective of lung cancer treatment